Opens in a new tab

Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG

Partnerships

December
16
2022
{post_date: F d, Y}

Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection

Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…
December
16
2022
{post_date: F d, Y}

Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection

Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…
December
16
2022
{post_date: F d, Y}

Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development

HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…
December
16
2022
{post_date: F d, Y}

New Project Trains AI on a Hard-to-Diagnose Cardiac Issue

Health Leaders: A start-up from the Mayo Clinic orbit is partnering with Pfizer to develop an AI-enhanced ECG that can detect cardiac amyloidosis, a progressive disease that's difficult to diagnose…
December
16
2022
{post_date: F d, Y}

Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease

NS Medical Devices: The research agreement with Pfizer will aid Anumana to develop an AI-enabled ECG algorithm to help detect patients who may be at risk of cardiac amyloidosis
December
16
2022
{post_date: F d, Y}

Anumana and Pfizer partner for cardiovascular disease detection

Medical Device Network: Health technology company Anumana and Pfizer have signed a multi-year agreement to develop an artificial intelligence electrocardiogram (AI-ECG) algorithm for the early detection of cardiac amyloidosis. Under…
December
16
2022
{post_date: F d, Y}

Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics

FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help…
December
15
2022
{post_date: F d, Y}

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

BioSpace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer Inc. for Anumana to develop an artificial intelligence electrocardiogram…
July
14
2022
{post_date: F d, Y}

Novartis turns to algorithms developer Anumana to apply AI to cardio conditions

Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions…
July
13
2022
{post_date: F d, Y}

Anumana Collaborates with Novartis Pharmaceuticals Corporation

AI TechPark: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…